AngioDynamics, Inc. (NASDAQ:ANGO – Get Free Report) CFO Stephen Trowbridge sold 23,615 shares of the business’s stock in a transaction on Thursday, October 29th. The shares were sold at an average price of $12.27, for a total value of $289,756.05. Following the transaction, the chief financial officer owned 280,461 shares of the company’s stock, valued at approximately $3,441,256.47. The trade was a 7.77% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
AngioDynamics Stock Down 2.9%
Shares of ANGO stock traded down $0.36 on Friday, hitting $11.99. The stock had a trading volume of 475,817 shares, compared to its average volume of 531,842. The company has a market cap of $504.18 million, a PE ratio of -15.37 and a beta of 0.30. The business has a 50 day moving average price of $14.26 and a 200 day moving average price of $12.46. AngioDynamics, Inc. has a one year low of $9.39 and a one year high of $16.29.
AngioDynamics (NASDAQ:ANGO – Get Free Report) last issued its quarterly earnings data on Thursday, October 8th. The medical instruments supplier reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.07. The firm had revenue of $80.92 million during the quarter, compared to analyst estimates of $80.51 million. AngioDynamics had a negative return on equity of 4.49% and a negative net margin of 10.12%. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. Equities research analysts expect that AngioDynamics, Inc. will post -0.26 EPS for the current year.
Institutional Trading of AngioDynamics
A number of large investors have recently added to or reduced their stakes in ANGO. Integrated Wealth Concepts LLC acquired a new stake in shares of AngioDynamics during the 2nd quarter valued at about $38,000. Pinnacle Wealth Planning Services Inc. acquired a new stake in AngioDynamics in the third quarter worth about $40,000. Legal & General Group Plc bought a new position in AngioDynamics in the second quarter valued at approximately $45,000. Public Employees Retirement System of Ohio acquired a new position in AngioDynamics in the second quarter valued at about $64,000. Finally, State of Wyoming bought a new stake in AngioDynamics in the second quarter valued at approximately $72,000. 89.43% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
ANGO has been the subject of several analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AngioDynamics in a research report on Thursday, October 15th. Wall Street Zen cut AngioDynamics from a “buy” rating to a “hold” rating in a report on Saturday, October 10th. HC Wainwright reduced their target price on AngioDynamics from $19.00 to $18.00 and set a “buy” rating on the stock in a research note on Tuesday, October 13th. Canaccord Genuity Group reiterated a “buy” rating and issued a $20.00 price target on shares of AngioDynamics in a report on Friday, October 9th. Finally, Zacks Research raised shares of AngioDynamics from a “strong sell” rating to a “hold” rating in a research note on Monday, October 5th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $19.00.
Read Our Latest Stock Report on ANGO
AngioDynamics Company Profile
AngioDynamics, Inc is a medical technology company that develops and manufactures minimally invasive devices used in vascular access, peripheral vascular disease treatment, oncology and surgical procedures. Its products are designed to support physicians in diagnosing and treating patients while reducing the need for more invasive interventions.
The company’s portfolio includes the Auryon system for atherectomy and thrombectomy procedures, the NanoKnife system, which uses irreversible electroporation technology for the ablation of certain soft-tissue tumors, and devices for vascular access and the management of procedure-related complications.
Recommended Stories
- Five stocks we like better than AngioDynamics
- Amazon’s Record Margins Couldn’t Stop the Sell-Off—Here’s Why
- DoorDash’s $17 Billion Bet on Instacart Faces a Long Regulatory Road Ahead
- FTC Puts A Wrinkle In the Cintas and UniFirst Merger
- Breaching the Valuation: The Real Reason Fortinet Dropped
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.
